Table 2: Summary of available data on SARS-COV-2 infections in heart transplant recipients Li et al. [3] Mathies et al. [5] Holzhauser et al. [6] Hsu et al. [7] Latif et al. [8] Hoek et al. [9] Kates et al. [10] Decker et al. [11] Fernandez- Ruiz et al. [12] Lee et al. [13] Caraffa et al Total, n (%) Number of patients 2 1 2 1 28 4 1 1 4 4 6 54 Baseline characteristics  Age (years) 51; 43 77 59; 75 39 64 (53.3–70.5) 75; 65; 51; 50 74 62 64; 67; 63; 38 15; 25; 1.1; 2.4 67 (59–74) 59.1  Time from HTx (years) 16.2; 2.6 17 8; 20 3 8.6 (4.2–14.5) 21; 10; 10; 6 23 0.4 13.8; 10; 17.9; 8.7 0.4; 3; 0.5; 2 12 (4.0–17.5) 9.4  Male gender 2 1 1 1 22 3 1 1 4 1 5 42 (78)  Arterial hypertension 0 1 2 1 20 NA NA 0 2 0 5 31 (63)  Diabetes mellitus 0 1 2 1 17 NA NA 0 1 0 0 22 (45)  Chronic kidney diseasea 0 1 2 0 10 NA NA 0 0 0 0 13 (27)  Lung disease 0 0 0 1 10 NA NA 1 1 0 0 13 (27)  PCI for CAV 0 1 0 0 NA NA NA 0 1 0 1 3 (14)  BMI >30 0 0 0 1 NA NA NA 0 NA 0 1 2 (12) COVID-19 onset symptoms  Fever 2 0 2 0 19 NA 1 1 4 3 6 38 (78)  Chest pain 0 0 0 1 5 NA 0 0 0 1 NA 7 (16)  Shortness of breath or cough 0 1 2 1 21 NA 1 1 4 2 6 39 (80)  Gastrointestinal symptoms 1 0 2 0 11 NA 0 0 1 1 2 18 (37) Treatment regimens  Maintenance immunosuppression   Cyclosporine 0 0 1 0 5 1 0 1 3 2 6 19 (35)   Mycophenolate  mofetil 2 1 2 1 19 2 0 1 4 1 4 37 (69)   Tacrolimus 2 0 1 1 22 3 1 0 1 1 0 32 (59)   Proliferation sig-  nal inhibitors 0 1 0 0 5 1 0 0 0 0 1 8 (15)   Azathioprine 0 0 0 0 0 0 0 0 0 2 0 2 (4)   Prednisone 0 0 0 1 19 2 0 1 4 2 0 29 (54) Number of immunosuppressive medications  1 0 0 0 0 3 0 1 0 0 0 1 2 (8)  2 2 1 2 0 8 3 0 0 0 1 5 14 (14)  3 0 0 0 1 16 1 0 1 4 2 0 9 (35)  4 0 0 0 0 1 0 0 0 0 0 0 0 (0) COVID-19 treatment  Hydroxychloroquine 0 1 2 1 18 3 0 1 4 1 5 36 (67)  Lopinavir/ritonavir 0 0 1 0 0 0 0 0 2 0 2 5 (9)  Remdesivir/placebo 0 0 0 1 0 0 0 0 0 0 0 1 (2)  Umifenovir 1 0 0 0 0 0 0 0 0 0 0 1 (2)  Oseltamivir 0 0 1 0 0 0 0 0 0 0 0 1 (2)  Ribavirin 1 0 0 0 0 0 0 0 0 0 0 1 (2)  IFN-b 0 0 0 0 0 0 0 0 1 0 0 1 (2)  Ganciclovir 2 1 0 0 0 0 0 0 0 0 0 3 (6)  Tocilizumab 0 0 2 0 6 0 0 0 0 0 0 8 (15)  Steroid bolus 1 0 1 0 8 0 0 1 0 1 5 17 (31)  IVIG 1 0 1 0 0 0 0 0 0 0 0 2 (4) Immunosuppressant strategy  Dose reduction 0 0 0 0 6 NA 0 0 0 1 5 12 (24)  At least 1 withdrawal 1 1 2 1 16 NA 0 0 4 1 1 27 (55) Acute graft rejection 0 0 0 0 0 NA 0 0 0 0 0 0 (0) Major outcomes  Hospitalized 2 1 2 1 22 NA 0 1 4 2 5 40 (82)  Need for ICU stay 0 1 1 1 NA NA 0 0 2 0 2 7 (33)  Invasive ventilation 0 0 1 0 NA NA 0 0 2 0 1 4 (19)  Self quarantined at home 0 0 0 0 6 NA 1 0 0 2 1 10 (20)  Death 0 0 0 0 7 1 0 0 1 0 2 11 (20)  Discharged 2 1 1 1 11 NA 0 0 2 2 3 23 (47)  Remained hospitalized 0 0 1 0 4 NA 0 1 1 0 0 7 (14) BMI: body mass index; CAV: cardiac allograft vasculopathy; HTx: heart transplant; IFN-b: interferon-beta; ICU: intensive care unit; IVIG: intravenous gamma globulin; NA: not available; PCI: percutaneous coronary intervention; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. a Defined by a glomerular filtration rate ˂30 ml/min and the presence of haemodialysis.